John Wiley & Sons, Inc. (JW.A)
|Net Income (ttm)||145.75M|
|Ex-Dividend Date||Jul 2, 2021|
|Day's Range||54.01 - 55.59|
|52-Week Range||29.42 - 65.66|
|Price Target||66.00 (+21.5%)|
|Est. Earnings Date||Dec 7, 2021|
John Wiley & Sons, Inc. operates as a research and learning company worldwide. The company operates through three segments: Research Publishing & Platforms, Academic & Professional Learning, and Education Services. The Research Publishing & Platforms segment offers scientific, technical, medical, and scholarly journals, as well as related content and services to learned societies, individual researchers, other professionals, and academic, corporate, and government libraries. This segment also publishes physical sciences and engineering, health ... [Read more...]
Financial PerformanceFinancial Statements
According to 3 analysts, the average rating for JW.A stock is "Hold." The 12-month stock price forecast is 66.00, which is an increase of 21.55% from the latest price.
HOBOKEN, N.J.--(BUSINESS WIRE)--John Wiley and Sons (NYSE: JW-A and JW-B), a global research and education company, today announced that its Board of Directors has declared a quarterly cash dividend of ...
Check out this week's thematic stock highlights, including SBUX and GM, courtesy of the Forbes AI Investor platform.
HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley Education Services, part of John Wiley and Sons Inc. (NYSE: JW-A) (NYSE: JW-B), recently signed five new university partnerships including University of Montana, Ne...
John Wiley & Sons, Inc. (JW.A) CEO Brian Napack on Q2 2021 Results - Earnings Call Transcript
Wiley has rebounded strongly from their Q4/2020 performance. Wiley should continue to see growth in all of their 3 main revenue streams.
Since I wrote my cautious piece on John Wiley & Sons, the shares have underperformed the market fairly massively. The financial picture has improved somewhat, and I think the dividend is sustainable. Im...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does John Wiley & Sons (JW.A) have what it takes?
John Wiley (JW.A) posts sales and earnings beat in first-quarter fiscal 2021. Gains in Research and Education categories boost performance.
On Sept. 3 before the market opened, John Wiley & Sons, Inc. (NYSE:JW.A) released its results for the fiscal 2021 first quarter, which ended July 31.
John Wiley & Sons, Inc. (JW.A) CEO Brian Napack on Q1 2021 Results - Earnings Call Transcript
John Wiley & Sons, Inc. Common Stock (NYSE: JW) unveils its next round of earnings this Thursday, September 03.
John Wiley & Sons' (JW.A) first-quarter fiscal 2021 performance might show adverse impacts of the coronavirus pandemic.
John Wiley & Sons (JW.A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
John Wiley & Sons: Distressed Stock With Decade-High Yield
John Wiley & Sons (JW.A) reported earnings 30 days ago. What's next for the stock?
HOBOKEN, N.J.--(BUSINESS WIRE)--John Wiley & Sons, Inc. (NYSE:JWA)(NYSE:JWB), a global leader in research and education, today announced that Peloton’s Chief People & Business Operations Officer and for...
LONDON & HOBOKEN, N.J.--(BUSINESS WIRE)--Cochrane is delighted to announce the signing of a new contract with John Wiley & Sons, Ltd. (NYSE:JWA) (NYSE:JWB), to publish the Cochrane Library for the next ...
John Wiley (JW.A) posts earnings and sales beat in fourth-quarter fiscal 2020. However, both top and bottom lines fall year over year.
John Wiley & Sons, Inc. (JW.A) CEO Brian Napack on Q4 2020 Results - Earnings Call Transcript
On June 11 before the market opened, Wiley & Sons, Inc. (JWA) released its results for the fiscal 2020 fourth quarter ended April 30.
Decline in print book sales is hurting John Wiley's (JW.A) performance. Also, the pandemic is leading to higher FX woes.
John Wiley & Sons Inc. JW.A, +8.39% JW.B, +9.98% lowered its fiscal 2020 financial outlook for adjusted profit and revenue, to include a revised estimate of the impact of the COVID-19 pandemic.